Market revenue in 2023 | USD 160.1 million |
Market revenue in 2030 | USD 246.2 million |
Growth rate | 6.3% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.5% in 2023. Horizon Databook has segmented the Australia point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
Several developments in the country by key players have contributed to the market growth. For instance, in March 2023, Microbix Biosystems, Inc. announced that it supports the Australian POC testing program for STIs in remote communities across Australia. Similarly, in 2020, ZiP Diagnostics received funding of USD 600,000 as part of the BioMedTech Horizons (BMTH) program’s Round 3, facilitated by MTPConnect.
The funds obtained through this grant were used to develop and commercialize innovative POC test products targeting different diseases, including STIs and SARS-CoV2. Furthermore, as per WHO, the country registered more than 5.8 million confirmed cases of COVID-19 and over 7,200 deaths between January 2020 and May 2022.
The impact of the pandemic was relatively low compared to other nations in Asia Pacific. This low number can be attributed to the largescale testing of individuals across the country. New South Wales had the highest testing rate for COVID19, with over 342,000 tests per 100,000 individuals.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia point-of-care molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Australia point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account